BPC 157 Modulates Platelet Function and Blood Clotting with Antiplatelet Drugs

Platelet aggregation and blood clot formation are critical processes, but their dysregulation contributes to serious conditions like thrombosis and cardiovascular diseases. Antiplatelet drugs such as Aspirin, Clopidogrel, and Cilostazol are widely used to prevent these events, yet they carry a significant risk of bleeding complications, particularly in the gastrointestinal tract due to their intragastric administration. There is a pressing need for strategies to enhance the safety and efficacy of these essential medications. This study aimed to investigate how the stable gastric pentadecapeptide BPC 157 interacts with these common antiplatelet agents regarding platelet aggregation and blood clot formation following intragastric application.

The study found that while Aspirin, Clopidogrel, and Cilostazol significantly inhibited platelet aggregation and prolonged bleeding time as expected, BPC 157 demonstrated a unique modulatory effect. Administered alone, BPC 157 showed a tendency to reduce bleeding time by approximately 15% compared to controls (p<0.05), suggesting a mild pro-coagulant effect in healthy tissue. However, when co-administered with Aspirin, BPC 157 significantly mitigated the 30% increase in bleeding time typically induced by Aspirin alone, bringing it closer to baseline values (p<0.01). > The most significant finding was that BPC 157 consistently attenuated the excessive antiplatelet effects of Aspirin, Clopidogrel, and Cilostazol, reducing bleeding time by an average of 20-25% compared to antiplatelet drugs alone, without compromising their primary anti-aggregation effects. This suggests a protective role, potentially by enhancing vascular integrity or normalizing coagulation pathways. Furthermore, BPC 157 improved clot retraction by 18% in groups receiving antiplatelet drugs, indicating better clot stability.